| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Immunology and
Surgery, and
Second Department of Anatomy, Kurume University School of Medicine, Fukuoka, Japan; and
§
Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Fukuoka, Japan
Peptide-based specific immunotherapy has resulted in tumor regression in some melanoma patients. However, tumor Ags and peptides for specific immunotherapy, except for treatment of melanomas, have not yet been well identified. In this study, we report a gene encoding a new squamous cell carcinoma (SCC) Ag recognized by cells of the HLA-A24-restricted and tumor-specific CTL line. This gene with 3958-bp length was transcribed from the chromosome 6q22 with six exons, and its mRNA was ubiquitously expressed in both SCCs and normal tissues, and partly expressed in adenocarcinomas. The deduced 958-aa sequence encoded by this gene showed no similarity to any known amino acid sequences. This gene product had a characteristic of an endoplasmic reticulum-resident protein. A 100-kDa protein was detected in the vast majority of SCCs from various tissues, in majority of renal cell carcinomas and brain tumors, and in about one-third of melanomas and adenocarcinomas from various organs other than the breast. In contrast, it was not expressed at all in any of the normal cells or tissues tested, including the testis and fetal liver. Three different peptides at positions 93–101, 161–169, and 899–907 of this Ag were recognized by this CTL line, and all of them induced HLA-A24-restricted and tumor-specific CTLs from PBMCs of SCC patients. Therefore, these peptides may be useful for peptide-based specific immunotherapy of HLA-A24+ patients with SCC in various organs, as well as for treatment of other cancer.
This article has been cited by other articles:
|
|
 |
|
  M. Maccarana, S. Kalamajski, M. Kongsgaard, S. P. Magnusson, A. Oldberg, and A. Malmstrom Dermatan Sulfate Epimerase 1-Deficient Mice Have Reduced Content and Changed Distribution of Iduronic Acids in Dermatan Sulfate and an Altered Collagen Structure in Skin Mol. Cell. Biol., October 15, 2009; 29(20): 5517 - 5528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Pacheco, A. Malmstrom, and M. Maccarana Two Dermatan Sulfate Epimerases Form Iduronic Acid Domains in Dermatan Sulfate J. Biol. Chem., April 10, 2009; 284(15): 9788 - 9795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Schuetz, M. Bonin, S. E. Clare, K. Nieselt, K. Sotlar, M. Walter, T. Fehm, E. Solomayer, O. Riess, D. Wallwiener, et al. Progression-Specific Genes Identified by Expression Profiling of Matched Ductal Carcinomas In situ and Invasive Breast Tumors, Combining Laser Capture Microdissection and Oligonucleotide Microarray Analysis. Cancer Res., May 15, 2006; 66(10): 5278 - 5286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Maccarana, B. Olander, J. Malmstrom, K. Tiedemann, R. Aebersold, U. Lindahl, J.-p. Li, and A. Malmstrom Biosynthesis of Dermatan Sulfate: CHONDROITIN-GLUCURONATE C5-EPIMERASE IS IDENTICAL TO SART2 J. Biol. Chem., April 28, 2006; 281(17): 11560 - 11568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yamada, H. Yano, Y. Takao, T. Ono, T. Matsumoto, and K. Itoh Nonmutated Self-Antigen-Derived Cancer Vaccine Peptides Elicit an IgE-Independent but Mast Cell-Dependent Immediate-Type Skin Reaction without Systemic Anaphylaxis J. Immunol., January 15, 2006; 176(2): 857 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Yajima, R. Yamanaka, T. Mine, N. Tsuchiya, J. Homma, M. Sano, T. Kuramoto, Y. Obata, N. Komatsu, Y. Arima, et al. Immunologic Evaluation of Personalized Peptide Vaccination for Patients with Advanced Malignant Glioma Clin. Cancer Res., August 15, 2005; 11(16): 5900 - 5911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hariu, Y. Hirohashi, T. Torigoe, H. Asanuma, M. Hariu, Y. Tamura, K. Aketa, C. Nabeta, K. Nakanishi, K. Kamiguchi, et al. Aberrant Expression and Potency as a Cancer Immunotherapy Target of Inhibitor of Apoptosis Protein Family, Livin/ML-IAP in Lung Cancer Clin. Cancer Res., February 1, 2005; 11(3): 1000 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Azuma, T. Sasada, H. Takedatsu, H. Shomura, M. Koga, Y. Maeda, A. Yao, T. Hirai, A. Takabayashi, S. Shichijo, et al. Ran, a Small GTPase Gene, Encodes Cytotoxic T Lymphocyte (CTL) Epitopes Capable of Inducing HLA-A33-restricted and Tumor-Reactive CTLs in Cancer Patients Clin. Cancer Res., October 1, 2004; 10(19): 6695 - 6702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shichijo, K. Azuma, N. Komatsu, M. Ito, Y. Maeda, Y. Ishihara, and K. Itoh Two Proliferation-Related Proteins, TYMS and PGK1, Could Be New Cytotoxic T Lymphocyte-Directed Tumor-Associated Antigens of HLA-A2+ Colon Cancer Clin. Cancer Res., September 1, 2004; 10(17): 5828 - 5836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ida, S. Kawaguchi, Y. Sato, T. Tsukahara, Y. Nabeta, H. Sahara, H. Ikeda, T. Torigoe, S. Ichimiya, K. Kamiguchi, et al. Crisscross CTL Induction by SYT-SSX Junction Peptide and Its HLA-A*2402 Anchor Substitute J. Immunol., July 15, 2004; 173(2): 1436 - 1443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yamaguchi, F. Tanaka, M. Ohta, H. Inoue, and M. Mori Identification of HLA-A24-Restricted CTL Epitope from Cancer-Testis Antigen, NY-ESO-1, and Induction of a Specific Antitumor Immune Response Clin. Cancer Res., February 1, 2004; 10(3): 890 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mine, Y. Sato, M. Noguchi, T. Sasatomi, R. Gouhara, N. Tsuda, S. Tanaka, H. Shomura, K. Katagiri, T. Rikimaru, et al. Humoral Responses to Peptides Correlate with Overall Survival in Advanced Cancer Patients Vaccinated with Peptides Based on Pre-existing, Peptide-Specific Cellular Responses Clin. Cancer Res., February 1, 2004; 10(3): 929 - 937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yamada, K. Kawano, M. Koga, S. Takamori, M. Nakagawa, and K. Itoh Gene and Peptide Analyses of Newly Defined Lung Cancer Antigens Recognized by HLA-A2402-restricted Tumor-specific Cytotoxic T Lymphocytes Cancer Res., June 1, 2003; 63(11): 2829 - 2835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Salgia, T. Lynch, A. Skarin, J. Lucca, C. Lynch, K. Jung, F. S. Hodi, M. Jaklitsch, S. Mentzer, S. Swanson, et al. Vaccination With Irradiated Autologous Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor Augments Antitumor Immunity in Some Patients With Metastatic Non-Small-Cell Lung Carcinoma J. Clin. Oncol., February 15, 2003; 21(4): 624 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Sato, Y. Nabeta, T. Tsukahara, Y. Hirohashi, R. Syunsui, A. Maeda, H. Sahara, H. Ikeda, T. Torigoe, S. Ichimiya, et al. Detection and Induction of CTLs Specific for SYT-SSX-Derived Peptides in HLA-A24+ Patients with Synovial Sarcoma J. Immunol., August 1, 2002; 169(3): 1611 - 1618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hirohashi, T. Torigoe, A. Maeda, Y. Nabeta, K. Kamiguchi, T. Sato, J. Yoda, H. Ikeda, K. Hirata, N. Yamanaka, et al. An HLA-A24-restricted Cytotoxic T Lymphocyte Epitope of a Tumor-associated Protein, Survivin Clin. Cancer Res., June 1, 2002; 8(6): 1731 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yamada, K. Kawano, M. Koga, T. Matsumoto, and K. Itoh Multidrug Resistance-associated Protein 3 Is a Tumor Rejection Antigen Recognized by HLA-A2402-restricted Cytotoxic T Lymphocytes Cancer Res., September 1, 2001; 61(17): 6459 - 6466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Dubinett, R. K. Batra, P. W. Miller, and S. Sharma Tumor Antigens in Thoracic Malignancy Am. J. Respir. Cell Mol. Biol., May 1, 2000; 22(5): 524 - 527. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
